<![CDATA[Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.]]>

Press Release|Articles|May 7, 2026 Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S. Author(s)Sylvester Comprehensive Cancer Center Listen0:00 / 0:00 Key Takeaways HTLV-1–associated ATLL clusters by birthplace, with >30-fold higher incidence among non-Hispanic Caribbean-born residents versus U.S./Canada-born populations, approaching endemic-region rates in some analyses. Florida’s large Caribbean-born population concentrates risk, with tens of thousands of births to mothers from HTLV-1–endemic regions and nearly 1 million such births nationally since 2000. Misclassification as PTCL-NOS likely masks true burden; sensitivity analyses reallocating excess PTCL-NOS nearly doubled estimated ATLL incidence among Caribbean-born individuals. Targeted prenatal HTLV-1 screening guided by maternal country of birth, coupled with breastfeeding counseling, is positioned as a pragmatic prevention strategy, paralleling Japan’s declines after nationwide programs.SHOW MORE Researchers at Sylvester identified populations in the US where this cancer may be largely preventable by addressing mother‑to‑child transmission of the virus. What if a deadly cancer could be stopped before it ever takes hold, not with a breakthrough drug or years of treatment but by preventing an infection passed quietly from mother to child?Adult T-cell leukemia/lymphoma (ATLL) is one of the few cancers for which this is true. The disease is rare, aggressive and often fatal, but it is also preventable. Its cause — human T-cell leukemia virus type 1, or HTLV-1 — is typically transmitted early in life, most often through breastfeeding. Decades later, that early exposure can surface as a fast-moving cancer with few effective treatment options.A team of researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and led by Paulo Pinheiro, M.D., Ph.D., professor of epidemiology and population health sciences at the Miller School, identified that this largely overlooked virus is present in U.S. residents born in HTLV-1–endemic regions, particularly the Caribbean. Maternal screening may be a potential prevention strategy. The findings have important implications for South Florida.“This is one of the few cancers where we understand the cause, the timeline and, most importantly, how to prevent it,” said Dr. Pinheiro, lead author of the Sylvester study, which was published in JAMA Oncology.Most people infected with HTLV-1 will never develop cancer. For those who do, the result is adult T-cell leukemia/lymphoma, a disease with a five-year survival rate below 25%.Globally, ATLL follows a map drawn by HTLV-1, clustering in southwestern Japan, the Caribbean, parts of South America and Africa. Japan responded decades ago with nationwide maternal screening programs that dramatically reduced mother-to-child transmission. In the United States, no comparable effort exists.That absence became the central question of Sylvester’s national study.Discovery: Seeing What the Data Was HidingTo answer that question, the research team turned to cancer registry data from all 50 U.S. states spanning nearly two decades. In total, more than 3,000 ATLL cases were identified, making the analysis the most comprehensive of its kind in the country.What emerged was a stark pattern. ATLL incidence varied not only by race but also by birthplace. Among non-Hispanic, Caribbean-born U.S. residents, incidence was more than 30 times higher than among people born in the U.S. or Canada. In some island-born populations, rates approached and, in certain analyses, exceeded those reported in historically endemic regions of Japan.“When we disaggregated by country of birth, the signal became impossible to ignore,” Dr. Pinheiro said. “Florida and New York stood out.”With one of the largest Caribbean-born populations in the country, the state of Florida accounted for nearly half of all U.S. cases. Tens of thousands of infants have been born in Florida over the past two decades to mothers from HTLV-1-endemic regions. Yet routine maternal screening is not part of U.S. prenatal care. Nationally, nearly 1 million children have been born in the United States since 2000 to mothers from HTLV-1 endemic regions.“Targeted maternal screening is not part of routine prenatal care,” Dr. Pinheiro said.The discovery reframed ATLL not as an unavoidable rarity but as a disease that could be stopped with early prevention.“Maternal screening is where cancer prevention and women’s health intersect most clearly for this disease,” said study co-author Sophia George, Ph.D., associate professor in the Miller School’s Department of Obstetrics, Gynecology and Reproductive Sciences and a member of Sylvester Comprehensive Cancer Center.Validation: Correcting a Diagnostic Blind SpotThe researchers also confronted the problem of misclassification. HTLV-1 testing is not routine when patients present with T-cell lymphomas, so ATLL is often coded instead as peripheral T-cell lymphoma not otherwise specified, or PTCL-NOS.To test whether this diagnostic blind spot was masking the true burden of disease, the team conducted sensitivity analyses that redistributed excess PTCL-NOS cases likely to represent undiagnosed ATLL. The result was striking. ATLL incidence among Caribbean-born individuals nearly doubled.In other words, the cancer was not just rare. It was underrecognized.“If we do not identify HTLV-1 and ATLL correctly, we miss the opportunity to prevent a fatal cancer decades before it develops,” Dr. Pinheiro said.Survival data reinforced the urgency. Outcomes were poor across all groups but worst among Caribbean-born patients, reflecting late diagnosis, aggressive disease biology or gaps in access to specialized care.Impact: A Roadmap for PreventionATLL is unusual among cancers because it is the only human cancer known to be caused by a retrovirus, its timeline is long and its prevention is proven. Interrupting mother-to-child transmission of HTLV-1 can effectively help eliminate lifetime risk of the disease, explained a Sylvester physician-scientist who studies ATLL.“Understanding how this cancer develops in patients with HTLV-1 infection gives us a chance to intervene much earlier, long before patients ever need treatment,” said Juan Ramos, M.D., senior author of the study and professor of hematology at the Miller School. “That’s where translational research can have its greatest impact.”Japan’s experience offers a real-world precedent. After decades of maternal screening and breastfeeding counseling, new ATLL diagnoses have begun to decline. The U.S., by contrast, continues to screen only blood donors, not pregnant women, even in high-risk populations.The study’s findings suggest a practical, targeted alternative. Rather than universal screening, which may not be cost-effective in low-prevalence populations, focused maternal screening based on country of birth could meaningfully reduce future cancer burden while minimizing unintended harm.“The goal is to move the window of intervention upstream,” Dr. Ramos said. “When we connect population data to biology, prevention becomes a realistic part of cancer care.” NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Related ContentFDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative DiseaseByChris RyanMay 7th 2026ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing StudiesByAshling Wahner May 7th 2026Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026ByCaroline SeymourMay 7th 2026Reigniting Your Curiosity During Fellowship ByMegan M. Dupuis, MD, PhDMay 7th 2026MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT ByCourtney FlahertyMay 6th 2026 Latest CMEVirtual EventMissouri Oncology Society1 Session is Available!View moreVideoProactive Adverse Event Management for HER2+ BTC TreatmentsRahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCOView moreMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView more Trending on OncLive1Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer2FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC3Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 20264ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go5Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma